Histone deacetylase 8 in neuroblastoma tumorigenesis

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 91-99

  Oehme, Ina ^a   Deubzer, Hedwig E ^a,d   Wegener, Dennis ^a   Pickert, Diana ^a   Linke, Jan Peter ^a   Hero, Barbara ^f   Kopp Schneider, Annette ^b   Westermann, Frank ^b   Ulrich, Scott M ^g   Von Deimling, Andreas ^c,e   Fischer, Matthias ^f   Witt, Olaf ^a,c,d  

^a Clinical Cooperation Unit Pediatric Oncology   (Germany)

^b Department of Biostatistics ^*  (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g ITHACA COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND 2; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; MESSENGER RNA; TRICHOSTATIN A; TUMOR MARKER; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NEUROBLASTOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION;

EID: 58849104486     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0684     Document Type: Article

References (44)

1. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
2. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
3. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
5. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002;11:1695-713.
6. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
7. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
8. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-55.
9. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93.
10. Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 2005;354:107-20.
11. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001;3:4239-42.
12. Krennhrubec K, Marshall BL, Hedglin M.Verdin E, Ulrich SM. Design and evaluation of "Linkerless" hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17:2874 - 8.
13. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
14. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63.
15. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
16. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3: 203-16.
17. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8.
18. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000:59:1261 -77.
19. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003:197:11 -7.
20. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
21. Shimada H, Chatten J, Newton WA, Jr., et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst1984;73:405-16.
22. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
23. Spitz R, Hero B,Westermann F, Ernestus K, Schwab M, Berthold F. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 2002;34:299-305.
24. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003;9:52-8.
25. Fischer M, Skowron M, Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 2005;7:89-96.
26. Witt 0, Monkemeyer S, Ronndahl G, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003;101:2001 - 7.
27. Hothorn T, Lausen B. Maximally selected rank statistics in R. R News 2002;2:3-5.
28. Deubzer HE, Ehemann V, Kulozik AE, et al. Antineuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 2008; 264:21 -28.
29. Waltregny D, Glenisson W.Tran SL, et al. Histone deacetylase HDAC8 associates with smooth muscle α-actin and is essential for smooth muscle cell contractility. FASEB J 2005;19:966-8.
30. Oehme I, Bosser S, Zornig M. Agonists of an ecdysone-inducible mammalian expression system inhibit Fas ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death Differ 2006;13:189-201.
31. Ehemann V, Sykora J.Vera-Delgado J, Lange A, Otto HF. Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett 2003;194:125-31.
32. Deubzer HE, Ehemann V, Westermann F, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008:122:1891 -900.
33. Wegener D.Wirsching F, Riester D, Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 2003:10:61 -8.
34. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451 -61.
35. Walton JD, Kattan DR, Thomas SK, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-45.
36. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000:97:10014-9.
37. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
38. Waltregny D, De Leval L, Glenisson W, et al. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 2004;165:553-64.
39. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A 2004;101:15064-9.
40. Lee H, Sengupta N, Villagra A, Rezai-Zadeh N, Seto E. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hESTIB) protein from ubiquitin-mediated degradation. Mol Cell Biol 2006;26:5259-69.
41. Choi JH, Kwon HJ.Yoon Bl, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
42. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58.
43. Zhang Z.Yamashita H,Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005:94:11 -6.
44. Keshelava N, Davicioni E, Wan Z, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007;99:1107-19.